The hypergonadotropic hypogonadism conundrum of classic galactosemia.
GALT deficiency
classic galactosemia
fertility preservation
folliculogenesis signaling pathways
galactose-1-phosphate uridylyltransferase
galactosemia type 1
hypergonadotropic hypogonadism
pregnancy
premature ovarian insufficiency
subfertility
Journal
Human reproduction update
ISSN: 1460-2369
Titre abrégé: Hum Reprod Update
Pays: England
ID NLM: 9507614
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
received:
29
08
2022
revised:
19
11
2022
pubmed:
14
12
2022
medline:
4
3
2023
entrez:
13
12
2022
Statut:
ppublish
Résumé
Hypergonadotropic hypogonadism is a burdensome complication of classic galactosemia (CG), an inborn error of galactose metabolism that invariably affects female patients. Since its recognition in 1979, data have become available regarding the clinical spectrum, and the impact on fertility. Many women have been counseled for infertility and the majority never try to conceive, yet spontaneous pregnancies can occur. Onset and mechanism of damage have not been elucidated, yet new insights at the molecular level are becoming available that might greatly benefit our understanding. Fertility preservation options have expanded, and treatments to mitigate this complication either by directly rescuing the metabolic defect or by influencing the cascade of events are being explored. The aims are to review: the clinical picture and the need to revisit the counseling paradigm; insights into the onset and mechanism of damage at the molecular level; and current treatments to mitigate ovarian damage. In addition to the work on this topic by the authors, the PubMed database has been used to search for peer-reviewed articles and reviews using the following terms: 'classic galactosemia', 'gonadal damage', 'primary ovarian insufficiency', 'fertility', 'animal models' and 'fertility preservation' in combination with other keywords related to the subject area. All relevant publications until August 2022 have been critically evaluated and reviewed. A diagnosis of premature ovarian insufficiency (POI) results in a significant psychological burden with a high incidence of depression and anxiety that urges adequate counseling at an early stage, appropriate treatment and timely discussion of fertility preservation options. The cause of POI in CG is unknown, but evidence exists of dysregulation in pathways crucial for folliculogenesis such as phosphatidylinositol 3-kinase/protein kinase B, inositol pathway, mitogen-activated protein kinase, insulin-like growth factor-1 and transforming growth factor-beta signaling. Recent findings from the GalT gene-trapped (GalTKO) mouse model suggest that early molecular changes in 1-month-old ovaries elicit an accelerated growth activation and burnout of primordial follicles, resembling the progressive ovarian failure seen in patients. Although data on safety and efficacy outcomes are still limited, ovarian tissue cryopreservation can be a fertility preservation option. Treatments to overcome the genetic defect, for example nucleic acid therapy such as mRNA or gene therapy, or that influence the cascade of events are being explored at the (pre-)clinical level. Elucidation of the molecular pathways underlying POI of any origin can greatly advance our insight into the pathogenesis and open new treatment avenues. Alterations in these molecular pathways might serve as markers of disease progression and efficiency of new treatment options.
Sections du résumé
BACKGROUND
Hypergonadotropic hypogonadism is a burdensome complication of classic galactosemia (CG), an inborn error of galactose metabolism that invariably affects female patients. Since its recognition in 1979, data have become available regarding the clinical spectrum, and the impact on fertility. Many women have been counseled for infertility and the majority never try to conceive, yet spontaneous pregnancies can occur. Onset and mechanism of damage have not been elucidated, yet new insights at the molecular level are becoming available that might greatly benefit our understanding. Fertility preservation options have expanded, and treatments to mitigate this complication either by directly rescuing the metabolic defect or by influencing the cascade of events are being explored.
OBJECTIVE AND RATIONALE
The aims are to review: the clinical picture and the need to revisit the counseling paradigm; insights into the onset and mechanism of damage at the molecular level; and current treatments to mitigate ovarian damage.
SEARCH METHODS
In addition to the work on this topic by the authors, the PubMed database has been used to search for peer-reviewed articles and reviews using the following terms: 'classic galactosemia', 'gonadal damage', 'primary ovarian insufficiency', 'fertility', 'animal models' and 'fertility preservation' in combination with other keywords related to the subject area. All relevant publications until August 2022 have been critically evaluated and reviewed.
OUTCOMES
A diagnosis of premature ovarian insufficiency (POI) results in a significant psychological burden with a high incidence of depression and anxiety that urges adequate counseling at an early stage, appropriate treatment and timely discussion of fertility preservation options. The cause of POI in CG is unknown, but evidence exists of dysregulation in pathways crucial for folliculogenesis such as phosphatidylinositol 3-kinase/protein kinase B, inositol pathway, mitogen-activated protein kinase, insulin-like growth factor-1 and transforming growth factor-beta signaling. Recent findings from the GalT gene-trapped (GalTKO) mouse model suggest that early molecular changes in 1-month-old ovaries elicit an accelerated growth activation and burnout of primordial follicles, resembling the progressive ovarian failure seen in patients. Although data on safety and efficacy outcomes are still limited, ovarian tissue cryopreservation can be a fertility preservation option. Treatments to overcome the genetic defect, for example nucleic acid therapy such as mRNA or gene therapy, or that influence the cascade of events are being explored at the (pre-)clinical level.
WIDER IMPLICATIONS
Elucidation of the molecular pathways underlying POI of any origin can greatly advance our insight into the pathogenesis and open new treatment avenues. Alterations in these molecular pathways might serve as markers of disease progression and efficiency of new treatment options.
Identifiants
pubmed: 36512573
pii: 6895523
doi: 10.1093/humupd/dmac041
pmc: PMC9976963
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
246-258Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.
Références
Hum Reprod Update. 2006 Sep-Oct;12(5):573-84
pubmed: 16835432
Am J Dis Child. 1966 Nov;112(5):477-8
pubmed: 5917984
Fertil Steril. 2017 Jul;108(1):168-174
pubmed: 28579413
J Anim Sci. 2004;82 E-Suppl:E40-52
pubmed: 15471814
Sci Rep. 2016 Jun 16;6:28207
pubmed: 27306703
Science. 2005 Feb 11;307(5711):935-9
pubmed: 15705855
Reprod Sci. 2016 Mar;23(3):352-64
pubmed: 26342052
J Inherit Metab Dis. 2018 Sep;41(5):791-797
pubmed: 29671189
Biochim Biophys Acta Mol Basis Dis. 2019 Nov 1;1865(11):165516
pubmed: 31362041
Ann N Y Acad Sci. 2008;1135:112-7
pubmed: 18574215
Lancet. 1979 Nov 10;2(8150):1021
pubmed: 91755
Antioxid Redox Signal. 2014 May 20;20(15):2361-71
pubmed: 23758052
Acta Endocrinol Suppl (Copenh). 1986;279:428-33
pubmed: 2946136
Mol Hum Reprod. 2021 Aug 7;27(8):
pubmed: 34314477
FASEB J. 1996 Mar;10(4):461-70
pubmed: 8647345
Fertil Steril. 1996 Mar;65(3):503-9
pubmed: 8774277
J Immunol. 2014 Jan 1;192(1):437-46
pubmed: 24307738
Fertil Steril. 1991 Jun;55(6):1197-9
pubmed: 2037114
Clin Genet. 2018 Feb;93(2):408-411
pubmed: 29044499
Hum Reprod. 2003 Oct;18(10):2031-8
pubmed: 14507817
J Clin Endocrinol Metab. 2013 Jul;98(7):E1257-65
pubmed: 23690308
J Pers Med. 2021 Jan 28;11(2):
pubmed: 33525536
Dev Biol. 2006 Nov 1;299(1):1-11
pubmed: 16970938
N Engl J Med. 1981 Apr 23;304(17):994-8
pubmed: 6782485
Reprod Fertil. 2021 Jun 25;2(3):R67-R84
pubmed: 35118398
Pediatr Res. 2010 Mar;67(3):286-92
pubmed: 19952866
Fertil Steril. 2009 Apr;91(4):1293.e13-6
pubmed: 19200962
Hum Reprod Update. 2015 Nov-Dec;21(6):787-808
pubmed: 26243799
FEBS J. 2021 Apr;288(8):2673-2696
pubmed: 33251685
J Ovarian Res. 2019 Oct 16;12(1):96
pubmed: 31619267
Eur J Pediatr. 2009 Jun;168(6):721-9
pubmed: 18813948
IUBMB Life. 2010 May;62(5):315-33
pubmed: 20209635
Endocrinology. 2006 Mar;147(3):1224-36
pubmed: 16339198
J Pediatr. 1985 Aug;107(2):261-3
pubmed: 3839528
J Pediatr. 2000 Dec;137(6):833-41
pubmed: 11113841
Nutrients. 2019 Jul 27;11(8):
pubmed: 31357608
Biochim Biophys Acta. 2014 Oct;1843(10):2150-63
pubmed: 24440275
J Inherit Metab Dis. 2013 Jan;36(1):29-34
pubmed: 22729817
Turk J Pediatr. 1996 Jul-Sep;38(3):335-44
pubmed: 8827903
J Assist Reprod Genet. 2018 Jul;35(7):1209-1217
pubmed: 29804175
J Proteome Res. 2014 Feb 7;13(2):385-94
pubmed: 24359113
Reprod Biomed Online. 2016 Dec;33(6):668-683
pubmed: 27742259
F1000Res. 2017 Nov 29;6:2069
pubmed: 29225794
Metabolism. 2018 Jun;83:188-196
pubmed: 29409891
Fertil Steril. 2005 Jun;83(6):1734-41
pubmed: 15950644
N Engl J Med. 2009 Feb 5;360(6):606-14
pubmed: 19196677
Eur J Hum Genet. 2014 Oct;22(10):1172-9
pubmed: 24549051
Hum Mol Genet. 2010 Feb 1;19(3):397-410
pubmed: 19843540
Orphanet J Rare Dis. 2018 Sep 19;13(1):164
pubmed: 30231941
Semin Reprod Med. 2015 Jul;33(4):270-5
pubmed: 26132931
Hum Reprod Update. 2010 Mar-Apr;16(2):177-88
pubmed: 19793842
Pharm Pat Anal. 2020 May;9(2):45-51
pubmed: 32314655
Heliyon. 2020 Sep 21;6(9):e05006
pubmed: 33005806
Biol Reprod. 2000 Nov;63(5):1278-84
pubmed: 11058530
J Inherit Metab Dis. 2011 Apr;34(2):357-66
pubmed: 20978943
Orphanet J Rare Dis. 2022 Mar 28;17(1):138
pubmed: 35346295
Reprod Biomed Online. 2011 Dec;23(6):697-703
pubmed: 22036907
Eur J Hum Genet. 2016 Jul;24(7):976-84
pubmed: 26733289
Oncotarget. 2017 Apr 11;8(15):25310-25322
pubmed: 28445976
Int J Biol Sci. 2019 Jan 29;15(4):726-737
pubmed: 30906205
Biochem Biophys Res Commun. 2016 Jan 29;470(1):205-212
pubmed: 26773505
Hum Reprod. 2006 Aug;21(8):2041-6
pubmed: 16613887
JIMD Rep. 2021 Jul 22;61(1):76-88
pubmed: 34485021
Clin Endocrinol (Oxf). 2006 Jun;64(6):603-10
pubmed: 16712660
PLoS One. 2009 Jul 09;4(7):e6186
pubmed: 19587782
Mol Genet Metab. 2014 Nov;113(3):177-87
pubmed: 25174965
Dis Model Mech. 2014 Jan;7(1):55-61
pubmed: 24077966
Ulster Med J. 1985 Oct;54(2):218-20
pubmed: 4095816
Cell Tissue Res. 2003 Mar;311(3):417-25
pubmed: 12658449
Orphanet J Rare Dis. 2019 Apr 27;14(1):86
pubmed: 31029175
Cell Prolif. 2021 Jan;54(1):e12954
pubmed: 33166004
Protein Sci. 2003 May;12(5):1051-9
pubmed: 12717027
Am J Hum Genet. 2004 Jul;75(1):106-11
pubmed: 15136966
PLoS One. 2011 Mar 21;6(3):e17894
pubmed: 21445305
Int J Mol Sci. 2022 Aug 04;23(15):
pubmed: 35955788
Fertil Steril. 2009 Jul;92(1):344-51
pubmed: 18684449
Adv Clin Exp Med. 2020 Apr;29(4):499-504
pubmed: 32356415
EMBO J. 2020 Nov 2;39(21):e104929
pubmed: 32954504
PLoS One. 2011;6(11):e27008
pubmed: 22073238
J Ovarian Res. 2022 Nov 21;15(1):122
pubmed: 36414970
Science. 2018 Oct 19;362(6412):356-360
pubmed: 30237246
J Inherit Metab Dis. 2017 Mar;40(2):169-170
pubmed: 27837294
Reproduction. 2020 Jan;159(1):R15-R29
pubmed: 31376814
J Inherit Metab Dis. 2011 Apr;34(2):387-90
pubmed: 20814826
Mol Genet Metab. 2022 Sep-Oct;137(1-2):33-39
pubmed: 35882174
Reprod Biol Endocrinol. 2012 Jun 29;10:49
pubmed: 22748101
Prenat Diagn. 1988 Nov;8(9):641-5
pubmed: 3211853
Clin Reprod Fertil. 1986 Apr;4(2):133-8
pubmed: 3091236
Fertil Steril. 2002 Jun;77(6 Suppl 5):S6-8
pubmed: 12069860
Endocr Rev. 2009 Aug;30(5):438-64
pubmed: 19589950
J Cell Physiol. 2018 Jan;233(1):226-237
pubmed: 28218391
Acta Paediatr. 1995 Jun;84(6):655-9
pubmed: 7670249
Gynecol Endocrinol. 2022 Feb;38(2):186-189
pubmed: 34730073
J Assist Reprod Genet. 2018 Jan;35(1):3-16
pubmed: 28932969
Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8204-9
pubmed: 15928081
Neonatology. 2016;110(3):225-30
pubmed: 27225493
Orphanet J Rare Dis. 2013 Jul 16;8:107
pubmed: 23866841
Hum Reprod Update. 1999 Sep-Oct;5(5):483-92
pubmed: 10582785
J Biol Chem. 2003 Nov 7;278(45):43885-8
pubmed: 12923184
J Inherit Metab Dis. 2020 May;43(3):392-408
pubmed: 31808946
Obstet Gynecol Surv. 2008 May;63(5):334-43
pubmed: 18419833
Br J Obstet Gynaecol. 1984 Feb;91(2):199-200
pubmed: 6421309
Lancet. 1979 Oct 6;2(8145):737-8
pubmed: 90818
PLoS One. 2012;7(2):e30709
pubmed: 22319579
Eur J Pediatr. 1997 Feb;156(2):116-20
pubmed: 9039515
Mol Genet Metab. 2012 Feb;105(2):212-20
pubmed: 22133299
Endocr Connect. 2021 Feb;10(2):240-247
pubmed: 33491660
Reprod Biol Endocrinol. 2012 Aug 20;10:58
pubmed: 22905678
Clin Pediatr (Phila). 1980 Jan;19(1):38-44
pubmed: 7351095
Cell. 2006 Jul 14;126(1):121-34
pubmed: 16839881
Dis Model Mech. 2013 Jan;6(1):84-94
pubmed: 22773758
Biochem Soc Trans. 2009 Oct;37(Pt 5):1099-103
pubmed: 19754460
Endocrinol Diabetes Metab Case Rep. 2016;2016:160026
pubmed: 27252868
Biochim Biophys Acta Mol Basis Dis. 2017 Dec;1863(12):3286-3293
pubmed: 28844959
Lancet. 1979 Dec 1;2(8153):1197
pubmed: 91932
Mol Genet Metab. 2007 Sep-Oct;92(1-2):78-87
pubmed: 17643331
Am J Physiol Endocrinol Metab. 2009 May;296(5):E985-92
pubmed: 19223655
Presse Med. 1984 Dec 8;13(44):2685-7
pubmed: 6240032
Dev Biol. 2008 Sep 1;321(1):197-204
pubmed: 18601916
Mol Genet Metab. 2006 Dec;89(4):316-22
pubmed: 16935538
JIMD Rep. 2016;27:47-53
pubmed: 26419375
Hum Mol Genet. 2009 Aug 1;18(15):2813-24
pubmed: 19423553
J Inherit Metab Dis. 2017 Mar;40(2):171-176
pubmed: 27858262
J Inherit Metab Dis. 2022 May;45(3):481-492
pubmed: 34918784
N Engl J Med. 1984 Jan 5;310(1):50
pubmed: 6689742
J Ovarian Res. 2017 Aug 16;10(1):56
pubmed: 28814333